Peptide Therapeutics Market Size, Share, Trends, Industry Analysis, and Forecast (2025 – 2031)

Peptide Therapeutics Market Size
The global peptide therapeutics market size was valued at $51.80 billion in 2025 and is projected to reach $75.58 billion by 2031, growing at a CAGR of 6.5% during the forecast period.

Peptide Therapeutics Market Overview
Peptide therapeutics represents a significant advancement in the pharmaceutical industry, leveraging short chains of amino acids that play crucial roles in various biological processes. These therapeutic agents are designed to target specific pathways and interactions within the body, offering a more tailored approach to treatment compared to traditional small molecule drugs. 
Companies can benefit from peptide therapeutics by developing innovative treatments for chronic diseases such as diabetes, obesity, and cancer, where peptides like glucagon-like peptide-1 (GLP-1) have demonstrated effectiveness in stimulating insulin secretion and regulating appetite. The growing body of research indicates that peptide drugs often exhibit high specificity and potency, leading to fewer side effects and more predictable metabolic profiles. As the market for peptide therapeutics expands—projected to grow significantly due to increasing incidences of metabolic disorders—pharmaceutical companies have the opportunity to capitalize on this trend by investing in research and development, enhancing their product portfolios, and potentially improving patient outcomes through novel therapeutic options.

Peptide Therapeutics Market Dynamics
The peptide therapeutics market is expected to witness significant growth in the future due to the increasing prevalence of chronic diseases, growing demand for personalized medicine due to the specificity and low toxicity of peptide therapeutics, and rising investments in research and development by pharmaceutical and biotechnology companies. However, the regulatory challenges and stringent approval processes for new peptide therapeutics, high costs associated with the development and manufacturing of peptide drugs, and limited awareness and understanding of peptide therapeutics among healthcare providers are restraining the growth of the market.

Furthermore, development of oral peptide therapies improving patient compliance and convenience, expansion of applications in immunotherapy and targeted treatments for complex diseases, and growing interest in peptide-based therapeutic vaccines for cancer treatment are the key trends propelling the peptide therapeutics market. 

Increasing Prevalence of Chronic Diseases is Driving the Peptide Therapeutics Market
The increasing prevalence of chronic diseases is significantly impacting the peptide therapeutics market, by driving demand for innovative treatment options. 
• For instance, the Centers for Disease Control and Prevention (CDC) reported that six in ten adults in the U.S. have at least one chronic disease, which underscores the urgent need for effective therapies. 
• Companies like Eli Lilly have been at the forefront of this trend; their peptide therapeutic, tirzepatide, demonstrated positive results in a Phase 3 clinical trial for heart failure with preserved ejection fraction (HFpEF) and obesity, showing improvements in symptoms and weight loss as of August 1, 2024. 
Additionally, the success of semaglutide, another peptide therapeutic used for type 2 diabetes, has been noted for its efficiency in reducing blood sugar levels and improving cardiovascular outcomes, further highlighting the therapeutic potential of peptides.
Government initiatives also play a role; increased funding and support for research into peptide-based therapies are evident as healthcare systems seek to address the growing burden of chronic diseases.

By Route of Administration, the Parenteral RouteSegment is projected to be the Largest Segment in the Peptide Therapeutics Market
Parenteral route is the largest segment in the peptide therapeutics market, driven by its advantages in bioavailability, rapid onset of action, and overall clinical effectiveness. 
• As of 2023, the parenteral route accounted for over 84% of the market share, driven by the increasing demand for effective treatments for chronic diseases such as diabetes and cancer. 
• For example, Eli Lilly launched Mounjaro (tirzepatide) in May 2022, a dual GLP-1 and GIP receptor agonist administered via injection, which has shown promising results in weight management and glycemic control for type 2 diabetes patients. 
• Similarly, Novo Nordisk's Ozempic (semaglutide) has gained traction since its launch in 2017, with continued positive outcomes reported in clinical trials concerning cardiovascular benefits and weight loss.
Government initiatives also bolster this segment; 
• For instance, the National Institutes of Health (NIH) in the U.S. has funded research into innovative peptide delivery systems that enhance the efficacy of parenteral formulations. 
Furthermore, advancements in drug delivery technologies, such as PEGylation—where polyethylene glycol is attached to peptides—are being explored to improve patient compliance and reduce side effects. 

By Geography, Asia Pacific Holds the Largest Share in the Market Revenue
Asia Pacific holds the largest share of the peptide therapeutics market, driven by rising chronic disease prevalence, increasing healthcare expenditure, and significant government initiatives aimed at enhancing healthcare infrastructure. 
• As of 2023, Countries like China and India are witnessing alarming rates of diabetes and cancer, with the International Diabetes Federation reporting that approximately 140 million people in China are living with diabetes. 
• For example, the Indian peptide therapeutics market is projected to reach $1.7 billion by 2033, driven by a growing aging population and increased healthcare costs, with an expected absolute dollar growth of $1.1 billion over the same period. 
Government initiatives, such as India's National Health Mission, aim to improve healthcare access and affordability, further boosting the demand for effective peptide therapies. Additionally, Japan's Ministry of Health has been actively promoting research in peptide therapeutics, contributing to a burgeoning market where companies like Takeda Pharmaceutical Company are investing heavily in R&D to develop next-generation peptide drugs. 

Key Target Audience:
• Pharmaceutical Companies 
• Biotechnology Firms 
• Healthcare Providers and Clinicians Specializing 
• Regulatory Bodies 
• Academic and Research Institutions 

List of the Key Players Profiled in the Report Includes: 
• Eli Lilly and Company
• Pfizer Inc
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Novo Nordisk A/S
• GlaxoSmithKline plc.
• Ironwood Pharmaceuticals, Inc.
• Radius Health, Inc.
• Ipsen Pharma
 
Recent Developments:
• In June 2025, Eli Lilly announced a collaboration with Camurus to develop long-acting peptide therapies targeting metabolic diseases. This partnership focuses on next-generation formulations that engage GLP‑1, GIP, and amylin receptors to enhance efficacy and dosing convenience.
• In June 2025, Amgen presented new Phase 2 data for its once-monthly GLP‑1/GIP dual agonist peptide MariTide at ADA 2025. The candidate showed promising efficacy in treating obesity and type 2 diabetes, supporting its advancement to late-stage development.
• In May 2025, Teva Pharmaceutical Industries highlighted its strategic shift toward innovation and peptide API manufacturing during its 2025 Innovation Day, underlining its role in supporting the development of complex peptide-based medicines.
• In March 2025, Takeda and Protagonist Therapeutics reported successful completion of the Phase 3 VERIFY trial for rusfertide, a hepcidin-mimetic peptide for polycythemia vera. The candidate met all efficacy endpoints and received FDA Orphan and Fast Track designations.
• In March 2025, AstraZeneca announced a partnership with Syneron Bio to co-develop macrocyclic peptide therapeutics, including PTH receptor and GLP-1/glucagon dual agonists aimed at improving treatment outcomes in metabolic disorders.
• In March 2025, Roche launched new obesity-focused trials under the ZUPREME peptide program, including GLP-1/GIP analogs. Additionally, the company entered a $5.3 billion licensing agreement with Zealand Pharma to co-develop petrelintide, an amylin-based peptide for weight loss.

Market Segmentation:
The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Type: 
• Generic 
• Innovative

Market by, Type of Manufacturers:
• In-house
• Outsourced

Market by, Type of Peptides:
• Small
• Medium
• Large 
 
Market by, Route of Administration: 
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal 
• Other Route of Administrations

Market by, Synthesis Technology: 
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Market by, Application:
• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain 
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Other Applications

Market by, Geography:
The peptide therapeutics market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:
• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

The report offers insights into the following aspects:
• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.

Table Of Content

1 Market Introduction             
    1.1 Market Definition         
    1.2 Research Scope and Segmentation         
    1.3 Stakeholders         
    1.4 List of Abbreviations         
              
2 Executive Summary             
              
3 Research Methodology             
    3.1 Identification of Data         
    3.2 Data Analysis         
    3.3 Verification         
    3.4 Data Sources         
    3.5 Assumptions         
              
4 Market Dynamics             
    4.1 Market Drivers         
    4.2 Market Restraints         
    4.3 Market Opportunities         
    4.4 Market Challenges         
              
5 Porter's Five Force Analysis             
    5.1 Bargaining Power of Suppliers         
    5.2 Bargaining Power of Buyers         
    5.3 Threat of New Entrants         
    5.4 Threat of Substitutes         
    5.5 Competitive Rivalry in the Market         
              
6 Global Peptide Therapeutics Market by, Type             
    6.1 Overview         
    6.2 Generic         
    6.3 Innovative         
              
7 Global Peptide Therapeutics Market by, Type of Manufacturers             
    7.1 Overview         
    7.2 In-house         
    7.3 Outsourced         
              
8 Global Peptide Therapeutics Market by, Type of Peptides             
    8.1 Overview         
    8.2 Small         
    8.3 Medium         
    8.4 Large         
              
9 Global Peptide Therapeutics Market by, Route of Administrations             
    9.1 Overview         
    9.2 Parenteral Route         
    9.3 Oral Route         
    9.4 Pulmonary         
    9.5 Mucosal         
    9.6 Other Route of Administrations         
              
10 Global Peptide Therapeutics Market by, Synthesis Technology             
    10.1 Overview         
    10.2 Solid Phase Peptide Synthesis (SPPS)         
    10.3 Liquid Phase Peptide Synthesis (LPPS)         
    10.4 Hybrid Technology         
              
11 Global Peptide Therapeutics Market by, Application             
    11.1 Overview         
    11.2 Cancer         
    11.3 Metabolic Disorders         
    11.4 Cardiovascular Disorders         
    11.5 Respiratory Disorders         
    11.6 Gastrointestinal Disorders         
    11.7 Infectious Diseases         
    11.8 Pain         
    11.9 Dermatological Disorders         
    11.10 Neurological Disorders         
    11.11 Renal Disorders         
    11.12 Other Applications         
              
12 Global Peptide Therapeutics Market by, Geography             
    12.1 Overview         
    12.2 North America         
             12.2.1 US
             12.2.2 Canada
             12.2.3 Mexico
    12.3 Europe         
             12.3.1 Germany
             12.3.2 France
             12.3.3 UK
             12.3.4 Italy
             12.3.5 Spain
             12.3.6 Rest of Europe
    12.4 Asia Pacific         
             12.4.1 China
             12.4.2 Japan
             12.4.3 India
             12.4.4 South Korea
             12.4.5 Australia
             12.4.6 New Zealand
             12.4.7 Rest of Asia Pacific
    12.5 South America         
             12.5.1 Brazil
             12.5.2 Argentina
             12.5.3 Chile
             12.5.4 Rest of South America
    12.6 Middle East & Africa         
             12.6.1 UAE
             12.6.2 Saudi Arabia
             12.6.3 Qatar
             12.6.4 Iran
             12.6.5 South Africa
             12.6.6 Rest of Middle East & Africa
              
13 Key Developments             
              
14 Company Profiling             
    14.1 Eli Lilly and Company         
             14.1.1 Business Overview
             14.1.2 Product/Service Offering
             14.1.3 Financial Overview
             14.1.4 SWOT Analysis
             14.1.5 Key Activities
    14.2 Pfizer Inc.         
    14.3 Amgen Inc.         
    14.4 Takeda Pharmaceutical Company Limited         
    14.5 AstraZeneca         
    14.6 Teva Pharmaceutical Industries Ltd.         
    14.7 Sanofi         
    14.8 F. Hoffmann-La Roche Ltd         
    14.9 Novartis AG         
    14.10 Novo Nordisk A/S         
    14.11 GlaxoSmithKline plc.         
    14.12 Ironwood Pharmaceuticals, Inc.         
    14.13 Radius Health, Inc.         
    14.14 Ipsen Pharma